LIFE-B:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund UnHedged Units (CAD)

ETF | Others |

Last Closing

CAD 23

Change

0.00 (0.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEQT:CA iShares Core Equity Portfolio

-0.03 (-0.09%)

CAD 6.91B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

N/A

CAD 6.63B
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

+0.13 (+0.42%)

CAD 6.19B
PHYS-U:CA Sprott Physical Gold Trust

+0.16 (+0.63%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

+0.10 (+0.27%)

CAD 4.54B
ZMMK:CA BMO Money Market Fund ETF Seri..

+0.01 (+0.02%)

CAD 4.20B
HXT-U:CA Global X S&P/TSX 60 Index ETF

+0.01 (+0.02%)

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

+0.20 (+0.67%)

CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

-0.07 (-0.56%)

CAD 3.29B
NSCB:CA NBI Sustainable Canadian Bond ..

+0.01 (+0.04%)

CAD 2.78B

ETFs Containing LIFE-B:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.80% 19% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.80% 18% F 19% F
Trailing 12 Months  
Capital Gain -7.63% 9% A- 16% F
Dividend Return 3.86% 82% B 73% C
Total Return -3.78% 10% F 18% F
Trailing 5 Years  
Capital Gain -2.25% 26% F 28% F
Dividend Return 33.49% 89% A- 77% C+
Total Return 31.24% 39% F 36% F
Average Annual (5 Year Horizon)  
Capital Gain 2.07% 44% F 42% F
Dividend Return 3.12% 47% F 38% F
Total Return 1.05% 80% B- 38% F
Risk Return Profile  
Volatility (Standard Deviation) 5.96% 74% C 88% B+
Risk Adjusted Return 52.36% 58% F 62% D
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.